CurrentEndo coverage · page 10 of 55

Diabetes, Obesity and Metabolism

Briefs 361–400 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

Diabetes Obes Metab31 May 2026
The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis
Meta-analysisT2D & other
Diabetes Obes Metab31 May 2026
Trends in Potentially Avoidable Hospitalisations Among People With Diabetes in Ireland; 2015–2024
Cohort studyT2D & other
Diabetes Obes Metab31 May 2026
Unveiling the BMI Risk Threshold for Osteoarthritis: Multi‐Database Causal and Nonlinear Evidence
Cohort studyObesity
Diabetes Obes Metab28 May 2026
Association of Physical Activity With All‐Cause and CVD Mortality Across Metabolic and Obesity Phenotypes
Cohort studyObesity
Diabetes Obes Metab28 May 2026
Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials
Meta-analysisObesity
Diabetes Obes Metab28 May 2026
Impact of Removing Restrictive Haemoglobin A1C Eligibility Criteria for Insulin Pump Therapy Funding for Children With Type 1 Diabetes in Ontario, Canada
Cohort studyTechnology
Diabetes Obes Metab28 May 2026
Risk of Psychiatric Worsening With GLP ‐1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression
Cohort studyT2D & other
Diabetes Obes Metab27 May 2026
A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes ( FABULINUS ): Rationale and Study Design
Trial designT1D
Diabetes Obes Metab27 May 2026
Randomised Controlled Feasibility Trial of Face‐To‐Face Diabetes Self‐Management Education Shows High Completion Rates Are Needed to Improve Patient‐Reported Outcomes
Randomized controlled trialT2D & other
Diabetes Obes Metab25 May 2026
GLP ‐1 Receptor Agonists and Risk of Age‐Related Macular Degeneration in Older Adults With Obesity: A Target Trial Emulation
Cohort studyObesity
Diabetes Obes Metab25 May 2026
Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle‐Aged but Not Older Men
Cohort study
Diabetes Obes Metab25 May 2026
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli‐D Study
Secondary analysisT2D & other
Diabetes Obes Metab25 May 2026
Real‐World Effectiveness and 12‐Month Persistence of a Semaglutide‐Supported Digital Weight‐Loss Service: A Retrospective Cohort Study in Germany
Cohort studyObesity
Diabetes Obes Metab24 May 2026
Prognostic Implications of Coronary Microvascular Dysfunction in ST ‐Elevation Myocardial Infarction by Obesity Status
Cohort studyObesity
Diabetes Obes Metab21 May 2026
Brain Serotonin Transporter Is Elevated in Obesity: Bayesian and Frequentist Meta‐Analyses
Meta-analysisObesity
Diabetes Obes Metab21 May 2026
Clinical Obesity and New‐Onset Atrial Fibrillation: A Population‐Based Cohort Study From the Kailuan Cohort
Cohort studyObesity
Diabetes Obes Metab21 May 2026
Comparative Associations of Traditional and New Obesity Framework With Cardio‐Kidney‐Metabolic Syndrome and All‐Cause Mortality: A Prospective Cohort Study
Cohort studyObesity
Diabetes Obes Metab21 May 2026
Dose–Response Effect of Glucagon on Glucose, Beta‐Cell Secretion and Metabolism in Healthy Individuals
Mechanistic study
Diabetes Obes Metab21 May 2026
Large‐Scale Plasma Proteomics Identifies Early Molecular Deviations and Improves Risk Prediction for Heart Failure Among Individuals With Obesity
Cohort studyObesity
Diabetes Obes Metab21 May 2026
Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes ( ONWARDS 10): A Randomised Controlled Trial
Randomized controlled trialT2D & other
Diabetes Obes Metab20 May 2026
The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis
Meta-analysisT2D & other
Diabetes Obes Metab19 May 2026
Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol
Trial designTechnology
Diabetes Obes Metab18 May 2026
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
Meta-analysisT2D & other
Diabetes Obes Metab18 May 2026
Advancing Early‐Stage Type 1 Diabetes Care: Future Focused Pathways for Identification, Screening, Diagnosis, and Monitoring
Guideline or statementT1D
Diabetes Obes Metab18 May 2026
Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
Cohort studyT2D & other
Diabetes Obes Metab18 May 2026
Health Inequities in Older Adults With Type 1 Diabetes: A Nationwide Registry Analysis of Sociodemographic and Clinical Profiles for Glycaemic Control and Complications
Cohort studyT1D
Diabetes Obes Metab17 May 2026
Association of Thyroid Function and Hormone Sensitivity With Abdominal Fat in Individuals With Overweight and Obesity
Cross-sectional studyObesity
Diabetes Obes Metab17 May 2026
Associations of Social Determinants and Lifestyle Factors With Incidence and Dynamic Progression of Type 2 Diabetes in the Chinese Population
Cohort studyT2D & other
Diabetes Obes Metab17 May 2026
Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat‐Free and Skeletal Muscle Mass in Overweight or Obese Individuals—A Systematic Review With Pairwise Meta‐Analysis and Network Meta‐Analysis of Randomized Controlled Studies
Meta-analysisObesity
Diabetes Obes Metab13 May 2026
Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database
Cohort studyObesity
Diabetes Obes Metab12 May 2026
Body Mass Index and All‐Cause, Cancer, and Cardiovascular Mortality in Adults Aged 16–50 Years With and Without Type 2 Diabetes: An Analysis of Primary Care Records in England
Cohort studyT2D & other
Diabetes Obes Metab12 May 2026
Intrapancreatic Fat Deposition and Metabolic Signatures Across Adiposity Phenotypes in Chinese Adults: A Computed Tomography Analysis
Cross-sectional studyT2D & other
Diabetes Obes Metab11 May 2026
Association Between SGLT2 Inhibitors and DPP ‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses
Case-control studyT2D & other
Diabetes Obes Metab11 May 2026
Beyond BMI : Reassessing the Prevalence of Obesity in Patients With MASLD Under the Lancet Commission Diagnostic Criteria
Cross-sectional studyObesity
Diabetes Obes Metab11 May 2026
Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts
Cohort studyLipids & liver
Diabetes Obes Metab11 May 2026
GLP ‐1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta‐Analysis
Meta-analysisT2D & other
Diabetes Obes Metab11 May 2026
Gold and Clarke Questionnaires Identify Different People With Insulin‐Treated Diabetes and Impaired Awareness of Hypoglycaemia in Almost 60% of Cases: A Post Hoc Analysis From the Hypo‐ METRICS Study
Secondary analysisT1D
Diabetes Obes Metab11 May 2026
Long‐Term Glycemic Exposure, Control Status and Cognitive Function in Older Adults: A Longitudinal Study
Cohort studyT2D & other
Diabetes Obes Metab11 May 2026
Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial
Secondary analysisT2D & other
Diabetes Obes Metab10 May 2026
Diabetic Peripheral Neuropathy May Be an Independent Risk Marker for Dementia and Cerebrovascular Disease
Cohort studyComplications

All 2,200 Briefs in ExploreShowing Briefs 361–400 of 2,200, newest first